Catalyst Dossier · compiled by CeliA 🧫

Galera Therapeutics, Inc. (GRTX)

Pharmaceutical Preparations · market cap $16M · as of 2026-07-19

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Galera Therapeutics (GRTX) is a micro-cap pharmaceutical company with a market cap of approximately $16M, a stock price near $0.10, and only 3 employees. Its lead asset, GC4419 (90mg), is in Phase 3 development for severe oral mucositis, with additional Phase 2 programs in pancreatic cancer, head and neck cancer, and radiation-induced oral mucositis at a lower dose (30mg/day).

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
GC4419	Phase 2	Pancreatic Cancer
Drug: GC4419	Phase 2	Head and Neck Cancer
GC4419 90mg	Phase 3	Oral Mucositis
Low Dose GC4419: 30mg/day	Phase 2	Radiation Induced Oral Mucositis

Price & technical context

3-month

+0.0%

6-month

-33.3%

12-month

-33.3%

52-wk range

$0.02–$0.05

vs 50-day MA

-9.9%

vs 200-day MA

-20.5%

Realized vol

218.9%

Max drawdown

-92.0%

Daily closes through 2025-12-11. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for GRTX (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.